Aromatase inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>David E. Volk m (Aromatase inhibitors moved to Aromatase inhibitor) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Aromatase inhibitors''', which inhibit the [[enzyme]] [[aromatase]] used biologically to produce estrogens, inhibit the biosynthetic production of [[estrogen]] [[steroid]]s. Because of this action, these inhibitors are sometimes used to treat cancerous tumors which are estrogen-sensitive. At present, three AIs are approved by the FDA<ref>[http://www.cancernet.gov/cancertopics/aromatase-inhibitors CancerNet]</ref> : | '''Aromatase inhibitors''', which inhibit the [[enzyme]] [[aromatase]] used biologically to produce estrogens, inhibit the biosynthetic production of [[estrogen]] [[steroid]]s. Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially [[breast cancer]] in postmenopausal women. At present, three AIs are approved by the FDA<ref>[http://www.cancernet.gov/cancertopics/aromatase-inhibitors CancerNet]</ref> : | ||
* [[anastrazole]] (Arimidex®) | * [[anastrazole]] (Arimidex®) | ||
Revision as of 18:02, 2 July 2010
Aromatase inhibitors, which inhibit the enzyme aromatase used biologically to produce estrogens, inhibit the biosynthetic production of estrogen steroids. Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially breast cancer in postmenopausal women. At present, three AIs are approved by the FDA[1] :
- anastrazole (Arimidex®)
- exemestane (Aromasin®)
- letrozole (Femara®)